OS Therapies (NYSEAMERICAN:OSTX) Receives “Buy” Rating from D. Boral Capital

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $20.00 price objective on the stock.

A number of other equities analysts have also recently commented on the company. Lake Street Capital lowered their target price on OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, OS Therapies currently has a consensus rating of “Moderate Buy” and an average target price of $18.50.

OS Therapies Stock Down 5.7%

Shares of NYSEAMERICAN OSTX opened at $1.33 on Thursday. The business’s 50 day moving average is $1.57 and its two-hundred day moving average is $1.83. OS Therapies has a 52-week low of $1.12 and a 52-week high of $2.98. The firm has a market cap of $46.83 million, a price-to-earnings ratio of -1.62 and a beta of -3.79.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter. Analysts anticipate that OS Therapies will post -0.64 EPS for the current fiscal year.

Hedge Funds Weigh In On OS Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in shares of OS Therapies during the second quarter worth approximately $63,000. Bridgeway Capital Management LLC acquired a new position in OS Therapies during the 2nd quarter worth approximately $47,000. Ground Swell Capital LLC acquired a new position in OS Therapies during the 3rd quarter worth approximately $40,000. CM Management LLC increased its position in shares of OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of OS Therapies in the 3rd quarter valued at $169,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.